Cambridge Healthtech Institute’s 5th Annual

Novel Antibody Constructs and Alternative Scaffolds
Innovative Engineering, Novel Products, Unique Targets and Immune Modulation
5-6 November 2014

In-depth research with the industry reveals the emergence of a wide range of exciting and innovative technologies with a variety of applications. In Europe there is a strong focus on platforms for bi-specific products, and on unique constructs and scaffolds, particularly on Fc engineering. This conference will present platforms for novel biotherapeutics with improved features such as enhanced access to the target site and better binding, and unique modes of action such as immune and complement activation. Presentations will cover target selection, and drug and platform discovery and development, and include challenges overcome and evidence for efficacy.

Preliminary Agenda


NOVEL APPLICATIONS OF BI-SPECIFIC TECHNOLOGY 

Seamless Transition from Mono- to Multi-Specific Antibodies Based on Light Chain Diversity

Nicolas Fischer, Ph.D., Head, Research, NovImmune SA

Benefits of Bispecific Antibodies with Two Independent Paratopes in the Fv Region

Roland Beckmann, Ph.D., CEO, CSO, Dutalys

A Novel Monovalent-Bispecific IgG Design

Partha S. Chowdhury, Ph.D., Principal Scientist, Antibody Discovery and Protein Engineering, MedImmune, Inc.


Fc ENGINEERING APPROACHES 

Antibody Engineering for Fc Silencing

Tilman Schlothauer, Ph.D., Senior Scientist, Functional Assays, Roche Diagnostics GmbH

Structural and Functional Insights into Neonatal Fc Receptor-Based Recycling Mechanisms

William Dall’Acqua, Ph.D., Director, R&D, Antibody Discovery and Protein Engineering-ADPE, MedImmune, Inc.


UNIQUE APPROACHES FOR CREATIVE ENGINEERING 

Philosophy and Principal Dogma behind Modern Discovery & Development of Biologics

Ralf Schumacher, Ph.D., Site Head, Large Molecule Research, Roche Penzberg & pRED

Protein Inactivation in vivo in Intrabody Expressing Mice

Stefan Dübel, Ph.D., Director, Biotechnology, Technische Universität Braunschweig

Natural and Engineered Sortases for the Masses: A New Enabling Technology for Protein Engineers

Christian Freund, Ph.D., Professor, Biochemistry, Freie Universitaet Berlin

Rationalising the Pharmacological Effect of a High-Affinity Neutralizing Serpin Antibody through Co-Crystallography

Katherine Vousden, Ph.D., Senior Scientist, Antibody Discovery and Protein Engineering, MedImmune


INNOVATIVE ENGINEERING FOR DIFFICULT-TO-REACH TARGETS 

Receptor-Mediated Delivery of a Bispecific Antibody into the Primate Brain: Challenges and Safety Findings

Mark S. Dennis, Ph.D., Principal Scientist, Antibody Engineering, Genentech, Inc.

Engineering Brain Shuttle Antibodies

Jens Niewöhner, Ph. D., Principal Scientist, Large Molecule Research, Pharma Research and Early Development, Roche Diagnostics GmbH


UNIQUE MODES OF ACTION 

Engineering of Probodies: Antibodies that Become Activated at the Target Site and Target Widely-Expressed Tumor-Specific Antigens

James West, Ph.D., Research Fellow, Protein Engineering, CytomX Therapeutics, Inc.

Novel Affitin Designs: Structural Basis for Two Modes of Action for Potent and Specific Inhibition of Glycosidases

Frédéric Pecorari, Ph.D., Researcher, Cancer Research Center of Nantes-Angers, University of Nantes


T CELL REDIRECTION AND IMMUNOMODULATION 

T Cell Redirection for Immune And Allergic Disorders

David Urech, Ph.D., CSO and Co-CEO, Numab AG

SM201/SM211: Two Anti-FcyRIIB mAbs Differing by a Single Amino Acid with Distinct Immunomodulatory Properties for the Treatment of Autoimmune Diseases

Peter Sondermann, Ph.D., CSO, SuppreMol GmbH